 |
This non-cross-linked HA filler is a breakthrough in orthopedic regenerative therapy, specifically formulated for intra-articular injection to alleviate knee osteoarthritis symptoms. With a 90 mg/3ml concentration, it mimics the viscoelastic properties of natural synovial fluid, replenishing depleted HA in degenerated joints to improve lubrication, reduce friction, and relieve pain for 3–6 months . Unlike cross-linked HA used in aesthetics, its non-cross-linked structure allows for optimal diffusion into joint tissues, making it a cornerstone of conservative osteoarthritis management.
This molecular weight range enables deep penetration into articular cartilage and synovial membranes, restoring the joint’s natural shock-absorbing capacity. Studies show it increases synovial fluid viscosity by 300% within 24 hours of injection, reducing joint friction during movement .
Beyond lubrication, it inhibits pro-inflammatory cytokines (e.g., TNF-α, IL-6) and matrix metalloproteinases (MMPs) that degrade cartilage. This dual action slows disease progression, with 78% of patients reporting reduced pain intensity at 3 months .
Manufactured under strict GMP conditions, the filler undergoes terminal sterilization via gamma irradiation, ensuring zero microbial contamination. It complies with ISO 10993 standards for biocompatibility, with no reported cases of immunogenic reactions in clinical trials .
Injected directly into the knee joint cavity by orthopedic specialists using sterile technique. A single 3ml dose is sufficient for mild to moderate osteoarthritis, while severe cases may require a second injection 2–4 weeks later .
Not recommended for patients with active joint infections, acute inflammation, skin diseases over the injection site, or those on anticoagulant therapy with INR > 2.5, as these increase bleeding risks .
Patients should avoid strenuous activity (e.g., running, heavy lifting) for 48 hours to allow optimal distribution. Full therapeutic benefits, including improved mobility and pain relief, typically manifest within 2–4 weeks as HA integrates with synovial fluid .
How long does pain relief last?
Results vary by disease severity: 68% of patients with mild osteoarthritis experience relief for 6 months, while those with moderate cases report benefits for 3–4 months .
Are there side effects?
Temporary reactions include joint swelling or tenderness, affecting ~5% of patients and resolving within 72 hours. Severe complications like septic arthritis are extremely rare (<0.1%) when strict sterile protocols are followed .
Can it be used with other treatments?
Yes, it complements physical therapy, NSAIDs, and corticosteroid injections. Combining HA with supervised exercise programs increases functional improvement by 40% compared to HA alone .
This non-cross-linked HA filler is a breakthrough in orthopedic regenerative therapy, specifically formulated for intra-articular injection to alleviate knee osteoarthritis symptoms. With a 90 mg/3ml concentration, it mimics the viscoelastic properties of natural synovial fluid, replenishing depleted HA in degenerated joints to improve lubrication, reduce friction, and relieve pain for 3–6 months . Unlike cross-linked HA used in aesthetics, its non-cross-linked structure allows for optimal diffusion into joint tissues, making it a cornerstone of conservative osteoarthritis management.
This molecular weight range enables deep penetration into articular cartilage and synovial membranes, restoring the joint’s natural shock-absorbing capacity. Studies show it increases synovial fluid viscosity by 300% within 24 hours of injection, reducing joint friction during movement .
Beyond lubrication, it inhibits pro-inflammatory cytokines (e.g., TNF-α, IL-6) and matrix metalloproteinases (MMPs) that degrade cartilage. This dual action slows disease progression, with 78% of patients reporting reduced pain intensity at 3 months .
Manufactured under strict GMP conditions, the filler undergoes terminal sterilization via gamma irradiation, ensuring zero microbial contamination. It complies with ISO 10993 standards for biocompatibility, with no reported cases of immunogenic reactions in clinical trials .
Injected directly into the knee joint cavity by orthopedic specialists using sterile technique. A single 3ml dose is sufficient for mild to moderate osteoarthritis, while severe cases may require a second injection 2–4 weeks later .
Not recommended for patients with active joint infections, acute inflammation, skin diseases over the injection site, or those on anticoagulant therapy with INR > 2.5, as these increase bleeding risks .
Patients should avoid strenuous activity (e.g., running, heavy lifting) for 48 hours to allow optimal distribution. Full therapeutic benefits, including improved mobility and pain relief, typically manifest within 2–4 weeks as HA integrates with synovial fluid .
How long does pain relief last?
Results vary by disease severity: 68% of patients with mild osteoarthritis experience relief for 6 months, while those with moderate cases report benefits for 3–4 months .
Are there side effects?
Temporary reactions include joint swelling or tenderness, affecting ~5% of patients and resolving within 72 hours. Severe complications like septic arthritis are extremely rare (<0.1%) when strict sterile protocols are followed .
Can it be used with other treatments?
Yes, it complements physical therapy, NSAIDs, and corticosteroid injections. Combining HA with supervised exercise programs increases functional improvement by 40% compared to HA alone .
